NEWS Russia targets counterfeit drug distributors
Te sale of counterfeit drugs is the target of new legislation proposed by the Russian government, according to news agency TASS.
Senator Anton Belyakov is behind an initiative that seeks to strengthen penalties for those manufacturing, storing, transporting and selling counterfeit drugs and medical devices.
Belyakov has proposed an amendment to section 238 of the Criminal Code, which would allow for jail sentences of between seven and ten years and a fine between 500,000 roubles ($11,000) and one million roubles for anyone responsible for the death of somebody from the consumption of a counterfeit drug.
He was critical of current measures that prosecute distributors only for health and safety violations.
He said: “Tis means that a counterfeit medicine destined to maintain health, but in fact being immediately dangerous to life, is equated to any other product produced with a violation of technological process.
“Counterfeit producers can get away with a fine of 100,000 roubles ($2,000),” he added.
Glenmark obtains FDA approval for generic omeprazole
Glenmark Generics has been granted approval to market a generic version of AstraZeneca’s ulcer treatment drug Prilosec (omeprazole delayed release capsules).
India-based Glenmark’s US subsidiary Glenmark Generics Inc (GGI) said its Abbreviated New Drug Application (ANDA) was granted final approval by
the US Food and Drug Administration (FDA) on November 5.
Te capsules are indicated for the short-term treatment of active duodenal ulcers in adults. Te FDA approval is for the 10, 20, and 40mg strengths. Te drug has several brand names including Acimax and Omez as well as Prilosec.
Glenmark’s current portfolio consists of 94 products authorised for distribution in the US and it has 72 ANDAs awaiting approval.
“In addition to these internal filings, GGI continues to
identify and explore external
development partnerships to supplement and accelerate the growth of the existing pipeline and portfolio,” the company said in a statement.
According to IMS Health, which provides information for the healthcare industry, Prilosec sales were approximately $520 million in the 12-month period ending September 2014.
Theranos sues over blood-collection trademark
Healthcare company Teranos has sued medical equipment supplier Becton Dickinson, seeking a judgment of non-infringement over a disputed trademark.
In a lawsuit filed at the US District Court for the Northern District of California, Palo Alto-based Teranos has sought to defend its attempt to register ‘Nanotainer’ as a trademark.
Te trademark was to be used in connection with a medical testing system developed by the company involving a tube to collect drops of blood.
According to Teranos, blood gathered this way could be used for a wide range of common tests without the need for large-scale storage of blood.
Te lawsuit stems from New Jersey-based Becton 6 Life Sciences Intellectual Property Review Volume 2, Issue 1
Dickinson’s opposition to a trademark application for ‘Nanotainer’ filed by Teranos in November last year.
It claimed that ‘Nanotainer’ was confusingly similar in sound, meaning and appearance to its ‘Microtainer’ mark.
Becton Dickinson filed an official opposition at the US Patent and Trademark Office’s Trademark Trial and Appeals Board on March 5.
But Teranos, which provides blood tests through the US-wide Walgreen pharmacy stores, asked the court to declare it is not infringing and that the terms are generic.
Neither company responded to a request for comment.
www.lifesciencesipreview
www.worldipreview.com
SLASHA /
SHUTTERSTOCK.COM
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44